FOR IMMEDIATE RELEASE
Contact: Samantha Platt Dangler
Sales and Marketing Manager
5710 Hoover Blvd
Tampa, FL 33634
800-995-4363 Ext 1509
AnazaoHealth Announces Full Continued Cooperation with FDA
to Promote Quality Assurance and Patient Safety
Efforts Build on Company’s Existing Commitment to Push the Bar for
Its Industry-leading Quality Assurance Program
TAMPA, Fla., March 8, 2013 — Staying true to its commitment to patient safety, specialty pharmacy AnazaoHealth Corporation has announced continued investment in quality assurance measures, including full cooperation with the U.S. Food and Drug Administration (FDA) to assess and improve quality practices. The specialty pharmacy has been in the compounding pharmacy business for more than 15 years, and more than 95 percent of its business remains patient-specific. Because it does not mass-produce medications and fills patient-specific prescriptions from licensed physicians, the pharmacy is not regulated by FDA Manufacturing Guidelines – instead adhering to USP<797> standards developed specifically for the compounding pharmacy industry and adopted into law by the Florida Board of Pharmacy. Despite this, AnazaoHealth is fully cooperating with the FDA, who inspected AnazaoHealth alongside state agency inspectors who found no deficiencies. The pharmacy continues to seek other internal and external audits to ensure the highest standards of quality and patient safety.
“While the debate is being waged on what standards are most appropriate for the compounding pharmacy industry, we remain focused on promoting quality assurance of the highest standard, no matter what,” said Jacob J. Beckel, chairman and CEO, AnazaoHealth. “That is why in addition to meeting or exceeding all standards of our regulating body -- the Florida Board of Pharmacy -- we are also implementing measures above-and-beyond, including actions based on some of the observations by the FDA.”
Throughout its history, AnazaoHealth has regularly sought both internal and external audits performed by industry experts to evaluate and guide its industry-leading quality assurance program, helping the company to meet and / or exceed all USP <797> sterile compounding and USP <795> non-sterile compounding standards. AnazaoHealth was among the first in the country to be awarded accreditation from the Pharmacy Compounding Accreditation Board (PCAB) in 2008, and remains accredited today. Pharmacists serve as Corporate Quality Director, Corporate Quality Manager, and as divisional Clinical Quality Managers. The company’s sterile compounding process involves no fewer than four different validation checks prior to completion of an order and makes extensive use of bar code technology, lessening chance of human error. AnazaoHealth is also planning further investment in enhancing its level of sterility testing, addressing some of the recommendations made during the recent FDA inspection.
“We know how important this is – this is the safety of our patients, and patient care is at the heart of our pharmacy,” said David Joseph, R.Ph, director of pharmacy, quality and regulatory compliance, AnazaoHealth. “We are proud of our quality program, and we will continue to make improvements to uphold the highest standards in the pharmacy industry.”
AnazaoHealth Corporation, a specialty pharmacy, has been in the compounding pharmacy business for over fifteen years, focusing on patient specific preparations serving the nuclear medicine, pain management and custom pharmacy markets, as well as providing drugs used in clinical trials. More information is available at www.anazaohealth.com